IP Library Granted Patent US 10,983,114
Granted Patent B2
US 10,983,114 · App. 15/580,708 · Granted Apr 20, 2021

Method for the in situ formation of bifunctional immunological complexes

Inventor: Andy Isamu Kokaji (Vancouver, CA)
Assignee: STEMCELL Technologies Inc.
G01N33/54326C07K1/22C07K16/00C07K16/283C07K16/2866C07K16/4283C07K16/44G01N33/54313G01N33/56977G01N33/80C07K2317/31C07K2317/32C07K2317/35
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,983,114
App. No.
15/580,708
Granted
Apr 20, 2021
Kind
B2
Abstract

An improved method for the preparation of tetrameric antibody complexes directly on the surface of target entities in a sample is described. In particular, this method involves linking, in the sample, a first target entity with a second target entity in a sample using antibodies with specificity for the first and second target entities.

Claims (22)

1. A method for linking a first target entity with a second target entity in an aqueous sample consisting essentially of:

(a) contacting the first target entity with a first antibody that is specific for the first target entity wherein the first antibody binds to the first target entity in the sample;

(b) adding a second antibody to the sample that binds the second target entity;

(c) adding a third antibody to the sample that is specific for the first and second antibodies wherein the third antibody binds to said first and second antibodies, thereby forming a tetrameric antibody complex;

(d) adding the second target entity wherein the second antibody binds to the second target entity, thereby linking the first and second target entity through the tetrameric antibody complex,

wherein the first and/or second antibodies are not mixed together with the third antibody to form the tetrameric antibody complex before they are added to the sample.

2. The method according to claim 1 , wherein the third antibody binds to the Fc portion of the first and second antibodies.

3. The method according to claim 1 , wherein the first target entity is selected from the group consisting of cells, bacteria, viruses, cell organelles, proteins and nucleic acids.

4. The method according to claim 3 wherein the first target entity is a cell.

5. The method according to claim 4 , wherein the first antibody is in a first antibody composition comprising antibodies specific for one or more antigens on the target cell(s).

6. The method according to claim 5 , wherein the first antibody composition comprises antibodies specific for one or more antigens selected from the group consisting of CD2, CD3, CD4, CD8, CD14, CD15, CD16, CD19, CD20, CD25, CD32, CD33, CD34, CD35, CD36, CD43, CD45, CD56, CD61, CD66b, CD123, CD127, CD138, alpha/beta TCR, gamma/delta TCR, and HLA-DR.

7. The method according to claim 4 , wherein the first target entity is a T cell.

8. The method according to claim 1 , wherein the second antibody binds to a particle or a bead.

9. The method according to claim 8 wherein the second antibody binds to PEG or dextran on the particle or bead.

10. The method according to claim 8 , wherein the particles are magnetic to form a magnetically labelled tetrameric antibody complex.

11. The method according to claim 10 , wherein the magnetically labelled tetrameric antibody complex first target entity is placed in a magnetic field of sufficient strength to separate the magnetically labelled tetrameric antibody complex first target entity from non-magnetically labelled tetrameric antibody complex first target entities.

12. A method for linking a first target entity with a second target entity in an aqueous sample consisting essentially of:

(a) contacting the first target entity with a first antibody that is specific for the first target entity wherein the first antibody binds to the first target entity in the sample;

(b) adding a second antibody to the sample that binds the second target entity;

(c) adding a third antibody to the sample that is specific for the first and second antibodies wherein the third antibody binds to said first and second antibodies, thereby forming a tetrameric antibody complex;

(d) adding the second target entity wherein the second antibody binds to the second target entity, thereby linking the first and second target entity through the tetrameric antibody complex, wherein the first and/or second antibodies are not mixed together with the third antibody to form the tetrameric antibody complex before they are added to the sample;

(e) removing the first target entity linked to the second target entity from the sample.

Assignments (2)
SECURITY INTEREST Recorded Jun 30, 2022
From: STEMCELL TECHNOLOGIES CANADA INC.
To: HSBC BANK CANADA
Reel/Frame 060544/0596 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 8, 2017
From: KOKAJI, ANDY ISAMU
To: STEMCELL TECHNOLOGIES INC.
Reel/Frame 044336/0008 →
Continuity (2)
Provisional Application 62173600 · Jun 10, 2015
Related Publication 20180188245A1 · Jul 5, 2018